Merck & Co., Inc. vs SOLAI Limited — how do they compare? Merck & Co., Inc. trades at $133.12 (market cap $321.77B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Merck & Co., Inc. is far larger — about 19279.2× SOLAI Limited's market cap, and Merck & Co., Inc. pays a 2.61% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| MRK | SLAI | |
|---|---|---|
Market Cap | $321.77B | $16.69M |
Sector | Health | Technology |
52-Week High | $131.84 | $26.74 |
52-Week Low | $77.60 | $2.74 |
Enterprise Value | $368.53B | $16.33M |
Dividend Yield | 2.61% | — |
Signals from Pluang's Aura AI — not financial advice
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
SLAI trades at $3.72 with no recent price movement, showing mixed technical signals despite a bullish overall rating. The company faces severe financial distress with negative profit margins (-134.63% net income margin) and declining revenue, compounded by NYSE delisting proceedings initiated in July 2026. Recent corporate actions include a 7:1 reverse stock split completed in July 2026 and the acquisition of a 51% stake in NEURALAND, signaling strategic shifts amid operational challenges.
The outlook remains highly speculative with significant execution and liquidity risks. While technical indicators suggest potential short-term momentum, fundamental weaknesses and delisting uncertainty create substantial downside risk. Investors should approach with caution given the company's negative profitability and regulatory challenges.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →